25-NET-05-RBI-PMC (RYZ401-101): Phase 1 First-in-Human (FIH), Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled with Actinium-225 (225Ac), in Subjects with Neuroendocrine Tumors (NETs) and Other Selected Soli